NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Sail Biomedicines

Sail Biomedicines

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.sail.bio/

Last Round

Grant

Dec 1, 2023

Total Funding Raised

$145.44M

Company Overview

Sail Biomedicines is a biotechnology company that develops a programmable medicine platform combining circular RNA technology (eRNA) and targeted nanoparticles (TNPs) with artificial intelligence to design and deploy medicines.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share, Services & Consulting

AI Layer

Application

Keywords

Endless RNAeRNAcircular RNAtargeted nanoparticlesTNPsprogrammable medicinesRNA therapeuticsplatform biotechcircRNAAI drug discoveryin vivo CAR-Tdrug deliveryautoimmune disease therapeuticsgenerative AImalaria vaccinemonoclonal antibody therapies

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sail Biomedicines Comparables

Compare Sail Biomedicines with similar companies based on industry and business-model similarity.

Sail Biomedicines comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Circurna
84%
AbbVie
84%
RiboX Therapeutics
84%

Sail Biomedicines Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 1, 2023
GrantDec 1, 2023
Series AMay 10, 2021
Series AOct 28, 2020

Sail Biomedicines Investors

Notable investors and investment history

Sail Biomedicines investors
InvestorRounds
Bill & Melinda Gates FoundationGrant
Flagship PioneeringSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 1, 2023

    Received $3.1M from the Bill & Melinda Gates Foundation.

  • Dec 1, 2023

    Received $4.3M from the Bill & Melinda Gates Foundation.

Sail Biomedicines Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sail Biomedicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sail Biomedicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Year Founded2023
Last FundingDec 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.